Patent Term Application for VYALEV (foscarbidopa and foslevodopa). Patent No. 9,446,059 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0162

Patent Term Application for VYALEV (foscarbidopa and foslevodopa). Patent No. 9,446,059

Documents

Comments

Description

OPEN

Comment Period OpensJan 15, 2025

Comment Period ClosesAug 29, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV FR Doc: 2026-13006	Jun 29, 2026	--

CDER

Patent Term Application

VYALEV (foscarbidopa and foslevodopa)

Covington & Burling LLP

AbbVie Inc.

Patent No. 9,446,059

OPEN